Robert Croce

Mr. Croce has served or is currently serving on the boards of 8 medtech companies and is chairman of 3 of them. Two were recently sold: Acclarent for $820M and Neotract for $1.1B.

Mr. Croce had a 36-year career at Johnson & Johnson where he held a series of senior positions, culminating with 12 years as Company Group Chairman. Under Mr. Croce’s leadership as Company Group Chairman, Cypher, the world’s first drug-eluting stent, was developed and commercialized, leading to the transformation of interventional cardiology.

Prior to this, Mr. Croce served as Worldwide Franchise Chairman of Cordis. Prior to Cordis, Mr. Croce was Worldwide Franchise Chairman for Ethicon Endo-Surgery which he founded and led to become the worldwide leader in endoscopic surgery.

Mr. Croce began his career with Johnson & Johnson in 1968 as a Sales Representative for Ortho Pharmaceuticals, where he was named Vice President of Marketing. In 1985, Mr. Croce moved to McNeil Pharmaceutical as Vice President of Business Development and later transferred to Ethicon, Inc. as Group Vice President, where he remained until he was named President in 1990. In 1992 he was promoted to Worldwide President, Ethicon Endo-Surgery.

Mr. Croce holds undergraduate and graduate degrees from Central Missouri State University.